Increased Fungal Infections while using Emerging Therapies (Biologics and Small-molecule Inhibitors) for Treating Skin Diseases: A Review

Q4 Medicine

Journal of Mycology and Infection Pub Date : 2021-09-30 DOI:10.17966/jmi.2021.26.3.57

J. Kim, Kyung Jae Lee

引用次数: 0

Abstract

Biologics, such as tumor necrosis factor-α and interleukin inhibitors, are commonly used for treating immunological skin diseases, including psoriasis, psoriatic arthritis, and atopic dermatitis. The cluster of differentiation inhibitors and immune checkpoint inhibitors has also been used for treating bullous disorders and melanoma, respectively. Other small-molecule inhibitors, such as JAK inhibitors, have been introduced for treating atopic dermatitis and alopecia areata. Hence, given the importance of cytokines and small molecules in antifungal immunity, using these new treatments are proposed to increase the risk of fungal infections. Thus, this review presents an overview of the reported incidences and possible mechanisms of fungal infections related to the use of biologics, including small-molecule inhibitors used for dermatological treatments.

查看原文本刊更多论文

使用紧急疗法（生物制品和小分子抑制剂）治疗皮肤病时真菌感染增加：综述

生物制品，如肿瘤坏死因子-α和白细胞介素抑制剂，通常用于治疗免疫性皮肤病，包括银屑病、银屑病关节炎和特应性皮炎。分化抑制剂和免疫检查点抑制剂的集群也已分别用于治疗大疱性疾病和黑色素瘤。其他小分子抑制剂，如JAK抑制剂，已被引入治疗特应性皮炎和斑秃。因此，鉴于细胞因子和小分子在抗真菌免疫中的重要性，建议使用这些新的治疗方法来增加真菌感染的风险。因此，这篇综述概述了与使用生物制剂（包括用于皮肤病治疗的小分子抑制剂）相关的真菌感染的发病率和可能机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Mycology and Infection Medicine-Infectious Diseases

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： The Journal of mycology and infection (Acronym: JMI, Abbreviation: J Mycol Infect) aims to publish articles of exceptional interests in the field of medical mycology. The journal originally was launched in 1996 as the Korean Journal of Medical Mycology and has reformed into the current state beginning on March of 2018. The contents of the journal should elucidate important microbiological fundamentals and provide qualitative insights to respective clinical aspects. JMI underlines the submission of novel findings and studies in clinical mycology that are enriched by analyses achieved through investigative methods. The journal should be of general interests to the scientific communities at large and should provide medical societies with advanced breadth and depth of mycological expertise. In addition, the journal supplements infectious diseases in adjunct to the field of mycology to address a well-rounded understanding of infectious disorders. The Journal of mycology and infection, which is issued quarterly, in March, June, September and December each year, published in English. The scope of the Journal of mycology and infection includes invited reviews, original articles, case reports, letter to the editor, and images in mycology. The journal is compliant to peer-review/open access and all articles undergo rigorous reviewing processes by our internationally acknowledged team of editorial boards. The articles directed to publication should encompass in-depth materials that employ scholastic values of mycology and various infectious diseases. Articles responding to critical methodology and outcomes which have potential to enhance better understanding of mycology and infectious diseases are also suitable for publication.